Alex J. Szubert

1.5k total citations
14 papers, 767 citations indexed

About

Alex J. Szubert is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Alex J. Szubert has authored 14 papers receiving a total of 767 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Alex J. Szubert's work include Multiple Myeloma Research and Treatments (11 papers), Peptidase Inhibition and Analysis (4 papers) and Cancer Treatment and Pharmacology (4 papers). Alex J. Szubert is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Peptidase Inhibition and Analysis (4 papers) and Cancer Treatment and Pharmacology (4 papers). Alex J. Szubert collaborates with scholars based in United Kingdom, United States and Uganda. Alex J. Szubert's co-authors include Faith E. Davies, Gareth J. Morgan, Walter M. Gregory, Mark T. Drayson, Roger G. Owen, Graham Jackson, Sue Bell, J. Anthony Child, A. John Ashcroft and Kim Cocks and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Alex J. Szubert

14 papers receiving 751 citations

Peers

Countries citing papers authored by Alex J. Szubert

Since Specialization

Citations

This map shows the geographic impact of Alex J. Szubert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex J. Szubert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex J. Szubert more than expected).

Fields of papers citing papers by Alex J. Szubert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex J. Szubert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex J. Szubert. The network helps show where Alex J. Szubert may publish in the future.

Co-authorship network of co-authors of Alex J. Szubert

This figure shows the co-authorship network connecting the top 25 collaborators of Alex J. Szubert. A scholar is included among the top collaborators of Alex J. Szubert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex J. Szubert. Alex J. Szubert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa 2024 ·Nature Communications ·(unknown), (unknown), Agnes Gwela, (unknown), (unknown), Abraham Siika, Mutsa Bwakura‐Dangarembizi, Victor Musiime, James A. Berkley, Alex J. Szubert, Diana M. Gibb, A Sarah Walker, Nigel Klein, Andrew J. Prendergast	5
2	Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial 2023 ·PLoS ONE ·(unknown), Alex J. Szubert, (unknown), (unknown), (unknown), Alasdair Bamford, Katja Doerholt, Diana M. Gibb, Victor Musiime, (unknown)	4
3	Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial 2012 ·Blood ·Charlotte Pawlyn, Faith E. Davies, Walter M. Gregory, Alex J. Szubert, Sue Bell, (unknown), Mark T. Drayson, Roger G. Owen, Graham Jackson, Nigel H. Russell, Gareth J. Morgan	3
4	Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial 2012 ·Blood ·Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Alex J. Szubert, Sue Bell, Mark T. Drayson, Roger G. Owen, A. John Ashcroft, Graham Jackson, J. Anthony Child	101
5	Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma 2011 ·Cancer Epidemiology Biomarkers & Prevention ·Kevin Boyd, Fiona M. Ross, Laura Chiecchio, Gian Paolo Dagrada, Zoë J. Konn, William Tapper, Brian A. Walker, Christopher P. Wardell, Walter M. Gregory, Alex J. Szubert, Faith E. Davies, Gareth J. Morgan	33
6	Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial 2011 ·The Lancet Oncology ·Gareth J. Morgan, J. Anthony Child, Walter M. Gregory, Alex J. Szubert, Kim Cocks, Sue Bell, Nuria Navarro-Coy, Mark T. Drayson, Roger G. Owen, Sylvia Feyler, A. John Ashcroft, Fiona M. Ross, Jenny Byrne, Huw Roddie, Claudius Rudin, Gordon Cook, Graham Jackson, Ping Wu, Faith E. Davies	117
7	MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease 2011 ·Blood ·Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Sue Bell, Alex J. Szubert, Gordon Cook, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham Jackson, J. Anthony Child	2
8	First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial 2010 ·The Lancet ·Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Kim Cocks, Sue Bell, Alex J. Szubert, Nuria Navarro-Coy, Mark T. Drayson, Roger G. Owen, Sylvia Feyler, A. John Ashcroft, Fiona Ross, Jenny Byrne, Huw Roddie, Claudius Rudin, Gordon Cook, Graham Jackson, J. Anthony Child	407
9	Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results 2010 ·Blood ·Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Sue Bell, Alex J. Szubert, Nuria Navarro-Coy, Mark T. Drayson, Roger G. Owen, Gordon Cook, Fiona M. Ross, Graham Jackson, J. A. Child	12
10	The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS. 2009 ·Blood ·Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Sue Bell, Alex J. Szubert, Kim Cocks, Nuria Navarro Coy, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham Jackson, J. Anthony Child	26
11	Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations. 2009 ·Blood ·David C. Johnson, Walter M. Gregory, Nicholas J. Dickens, Brian A. Walker, Alex J. Szubert, Faith E. Davies, Brian G.M. Durie, Brian G. Van Ness, Gareth J. Morgan	2
12	Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation 2008 ·Blood ·Gareth J. Morgan, Graham Jackson, Faith E. Davies, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, (unknown), Alex J. Szubert, Sue Bell, Fiona Ross, (unknown)	36
13	Severe Sequence-Specific Toxicity When Capecitabine Is Given After Fluorouracil and Leucovorin 2008 ·Journal of Clinical Oncology ·I. Hennig, Jay Naik, Sarah Brown, Alex J. Szubert, David Alan Anthoney, David Jackson, (unknown), S. M. Crawford, (unknown), Julia Brown, Michel Seymour	16
14	Genetic Variation in ADME Genes Is Associated with Thalidomide Related Peripheral Neuropathy in Multiple Myeloma Patients. 2008 ·Blood ·David C. Johnson, (unknown), Alex J. Szubert, Walter M. Gregory, J. A. Child, Faith E. Davies, Brian G.M. Durie, Brian G. Van Ness, Gareth J. Morgan	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact